You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

 

Online download statistics by month:

Online download statistics by month: September 2022 to September 2025

AbstractFullPdf
Sep 2022454468166
Oct 2022368395133
Nov 202216516792
Dec 202212713049
Jan 202310810943
Feb 202310410446
Mar 2023545522
Apr 2023676827
May 2023576432
Jun 2023576323
Jul 2023737340
Aug 2023798032
Sep 2023656617
Oct 202317217337
Nov 2023757531
Dec 2023555629
Jan 2024444632
Feb 2024505231
Mar 20245050103
Apr 2024606040
May 2024525233
Jun 2024636245
Jul 2024646544
Aug 2024424167
Sep 2024353528
Oct 2024525836
Nov 202415715834
Dec 2024798242
Jan 2025575744
Feb 202512512537
Mar 2025515150
Apr 202510010250
May 2025555732
Jun 2025323227
Jul 2025110
Sep 2025110
Total325033331594